Literature DB >> 10631965

Seroprevalence of hepatitis C in a sample of middle class substance abusers.

H D Abraham1, S Degli-Esposti, L Marino.   

Abstract

Hepatitis C (HCV) is an indolent and often fatal disease affecting four million Americans commonly associated with low socioeconomic status. We assessed its prevalence in a sample of 334 consecutively admitted middle class substance abusers in a private urban hospital, and ascertained risk factors for its transmission. We found that the point prevalence rate for HCV was 27.7% among all substance abusers, and 76.7% among intravenous drug users. Using logistic regression, we found risk factors associated with HCV were intravenous drug use, needle sharing, prior liver disease, opioid dependence, HIV infection, and benzodiazepine dependence. Not found to increase infective risk were lower social class, male gender, African-American race, male homosexuality, unemployment, and the absence of private health insurance. Multiple viral genotype types were identified in this sample, suggesting diverse sources of transmission in the sample. This study documents an epidemic of HCV in an American middle class sample.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10631965     DOI: 10.1300/J069v18n04_07

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  8 in total

Review 1.  Measuring sexual behaviour: methodological challenges in survey research.

Authors:  K A Fenton; A M Johnson; S McManus; B Erens
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs.

Authors:  Paxton Bach; Geoffrey Walton; Kanna Hayashi; M-J Milloy; Huiru Dong; Thomas Kerr; Julio Montaner; Evan Wood
Journal:  Am J Public Health       Date:  2016-03-17       Impact factor: 9.308

3.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

4.  Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.

Authors:  Laura F McNicholas; Amber M Holbrook; Kevin E O'Grady; Hendrée E Jones; Mara G Coyle; Peter R Martin; Sarah H Heil; Susan M Stine; Karol Kaltenbach
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

5.  Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine.

Authors:  Amber M Holbrook; Jason K Baxter; Hendrée E Jones; Sarah H Heil; Mara G Coyle; Peter R Martin; Susan M Stine; Karol Kaltenbach
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

6.  Predicting implementation from organizational readiness for change: a study protocol.

Authors:  Christian D Helfrich; Dean Blevins; Jeffrey L Smith; P Adam Kelly; Timothy P Hogan; Hildi Hagedorn; Patricia M Dubbert; Anne E Sales
Journal:  Implement Sci       Date:  2011-07-22       Impact factor: 7.327

7.  A Training Model for Implementing Hepatitis Prevention Services in Substance Use Disorder Clinics: A Qualitative Evaluation.

Authors:  Hildi J Hagedorn; Nancy Rettmann; Eric Dieperink; Astrid Knott; Bruce E Landon
Journal:  J Gen Intern Med       Date:  2015-08       Impact factor: 5.128

Review 8.  Alcohol use in opioid agonist treatment.

Authors:  Seonaid Nolan; Jan Klimas; Evan Wood
Journal:  Addict Sci Clin Pract       Date:  2016-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.